Full TitleA Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO)
The purpose of this study is to assess the safety and effectiveness of the investigational drug adavosertib in women with uterine serous carcinoma that came back or continued to grow despite prior treatment that included platinum-based chemotherapy. Adavosertib works by inhibiting WEE1, an enzyme involved in uterine cancer growth. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have uterine serous carcinoma that came back or continued to grow despite prior treatment that included platinum-based chemotherapy.
- At least 3 weeks must pass since the completion of chemotherapy and 4 weeks since the completion of immunotherapy and receipt of adavosertib.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for women age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Maria Rubinstein at 646-888-6954.